PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while GNPX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-57.23%
Negative gross profit growth while GNPX is at 54.37%. Joel Greenblatt would examine cost competitiveness or demand decline.
5.53%
EBIT growth below 50% of GNPX's 38.58%. Michael Burry would suspect deeper competitive or cost structure issues.
5.53%
Operating income growth under 50% of GNPX's 38.58%. Michael Burry would be concerned about deeper cost or sales issues.
5.62%
Net income growth under 50% of GNPX's 38.58%. Michael Burry would suspect the firm is falling well behind a key competitor.
13.79%
EPS growth under 50% of GNPX's 40.88%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
13.79%
Diluted EPS growth under 50% of GNPX's 40.88%. Michael Burry would worry about an eroding competitive position or excessive dilution.
10.10%
Share count expansion well above GNPX's 4.04%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.10%
Diluted share count expanding well above GNPX's 4.01%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth under 50% of GNPX's 45.72%. Michael Burry might suspect questionable revenue recognition or rising costs.
17.73%
FCF growth under 50% of GNPX's 48.27%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
94.36%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
80.21%
3Y OCF/share CAGR 1.25-1.5x GNPX's 72.85%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-551.14%
Negative 10Y net income/share CAGR while GNPX is at 91.30%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.20%
5Y net income/share CAGR similar to GNPX's 91.30%. Walter Schloss might see both on parallel mid-term trajectories.
81.22%
3Y net income/share CAGR similar to GNPX's 81.28%. Walter Schloss would attribute it to shared growth factors or demand patterns.
1992.70%
Equity/share CAGR of 1992.70% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-67.70%
Negative 5Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-15.48%
Negative 3Y equity/share growth while GNPX is at 7.80%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.36%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
-16.56%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.08%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.